Clinical Trial Update: Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial [Phase 2]

View source ↗

Summary

A Phase 2 multicenter, single-arm trial evaluating the combination of tislelizumab, fruquintinib, and metronidazole in advanced, mismatch repair-proficient or m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• METRONIDAZOLE (Metronidazole)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Jing-yuan Fang, MD, Ph. D | Conditions: Colorectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING